Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) will report its fourth quarter and full year 2025 financial results and corporate highlights after U.S. market close on February 26, 2026. The company is a clinical-stage small molecule precision medicine firm focused on cancer and genetic disease therapies.

News Market Reaction – RLAY

-1.81%

6 alerts

-1.81% Session close to close

-3.4% Trough in 24 hr 20 min

$1.51B Market Cap

0.1x Rel. Volume

In the Feb 20 session, RLAY declined 1.81%, reflecting a mild negative market reaction. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Relay Therapeutics’ fourth quarter and full-year 2025 resul...

Analysis

This announcement sets the timetable for Relay Therapeutics’ fourth quarter and full-year 2025 results on February 26, 2026. Investors may contextualize the upcoming release against prior disclosures, including Q3 2025 cash of $596.4M with an expected runway into 2029 and recent Breakthrough Therapy designation for zovegalisib. Key considerations include any updates to cash runway, R&D spending trends, and progress across core clinical programs, as well as how management frames upcoming milestones.

Key Figures

Earnings release date: February 26, 2026

1 metrics

Earnings release date February 26, 2026 Scheduled Q4 and full-year 2025 results and corporate highlights

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 04	Investor conference	Neutral	-2.1%	Announced participation in Guggenheim Emerging Outlook: Biotech Summit 2026.
Feb 03	FDA designation win	Positive	+6.4%	FDA Breakthrough Therapy designation for zovegalisib plus fulvestrant in breast cancer.
Dec 12	Clinical efficacy data	Positive	+3.1%	Reported positive PFS and ORR subset data from ReDiscover breast cancer program.
Nov 06	Quarterly earnings	Positive	-0.3%	Q3 2025 results with strong cash of $596.4M, runway into 2029, lower expenses.
Nov 03	Investor conferences	Neutral	-2.8%	Planned participation in two November 2025 healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent RLAY news has mostly seen price moves align with fundamentals: positive clinical and FDA designation updates were followed by gains, while a stronger-looking Q3 2025 earnings release saw a slight divergence with a small decline.

Recent Company History

Over the past several months, Relay Therapeutics has highlighted clinical and regulatory progress alongside steady corporate activity. The company secured FDA Breakthrough Therapy designation for zovegalisib and reported encouraging subset efficacy data from the ReDiscover program, both followed by positive stock reactions. Q3 2025 results showed $596.4M in cash with expected runway into 2029 and lower R&D and G&A expenses, though shares slipped modestly. Multiple conference and investor event participations drew smaller, mixed reactions. Today’s earnings-date announcement fits into this cadence of regular updates.

Key Terms

precision medicine

1 terms

precision medicine medical

"a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Pete Rahmer
prahmer@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics (RLAY) announce its Q4 and full year 2025 results?

Relay will announce results after U.S. markets close on February 26, 2026. According to the company, the release covers fourth quarter and full year 2025 financial results and corporate highlights, timed for post-market disclosure to investors.

What will Relay Therapeutics (RLAY) report on February 26, 2026?

Relay will report its fourth quarter and full year 2025 financial results and corporate highlights. According to the company, the announcement will summarize financial performance and key corporate developments for 2025.

Where is Relay Therapeutics (RLAY) headquartered and what does it do?

Relay is headquartered in Cambridge, Mass. and is a clinical-stage precision medicine company. According to the company, it develops small molecule therapies targeting cancer and genetic diseases.

What is the stock symbol for Relay Therapeutics and where does it trade?

Relay Therapeutics trades as RLAY on Nasdaq. According to the company, investors can follow corporate filings and market updates under the Nasdaq ticker RLAY.

Will the February 26, 2026 announcement include clinical updates from Relay Therapeutics (RLAY)?

The announcement will include corporate highlights, which may cover clinical developments alongside financials. According to the company, corporate highlights are being released with the Q4 and full year 2025 results.

How should investors prepare for Relay Therapeutics' (RLAY) February 26, 2026 release?

Investors should review prior financials and clinical disclosures ahead of the post-market release. According to the company, the update will present both financial results and corporate highlights for 2025.